Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Microarrays & Multiplexing » Cytox Gets CE Mark for Alzheimer's Disease Genetic Risk Test

Cytox Gets CE Mark for Alzheimer's Disease Genetic Risk Test

Feb 24, 2021
|
staff reporter

NEW YORK – Cytox said on Wednesday that it has garnered CE marking for its GenoScore-Lab genetic risk test for Alzheimer's disease and has launched the test in Europe.

GenoScore-Lab analyzes an individual's genes for more than 100,000 SNPs associated with the risk of developing Alzheimer's disease. According to a company spokesperson, the test runs on a custom Axiom array on the Thermo Fisher Scientific GeneTitan platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.